miR-133和EGFR在结肠癌组织中的表达及其临床意义

doi:10.3969/j.issn.1671-7171.2020.08.029

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨mirR-133和表皮生长因子受体(EGFR)在结肠癌组织中的表达水平及其临床意义。【方法】收集手术切除的结肠癌组织和癌旁正常组织各70例,采用实时荧光定量PCR(RT-PCR)检测组织中的mirR-133和EGFR表达水平;采用Pearson分析mirR-133和EGFR的相关性;采用Kaplan-Meier(K-M)生存曲线分析其表达水平对患者生存率的影响。【结果】 miR-133在结肠癌组织中的表达水平明显低于正常组织,而EGFR表达显著高于正常组织,其差异均具有统计学意义(P<0.05)。结肠癌组织中mirR-133和EGFR的表达呈负相关(r=-0.4941,P<0.01)。miR-133、EGFR表达均与临床分期、淋巴结转移、TNM分期、病理分级相关。miR-133高表达但患者生存率高于低表达组(P<0.05),而EGFR高表达但患者的生存率低于低表达组(P<0.05)。【结论】 miR-133和EGFR在结肠癌组织中的表达增高,两者呈负相关,均与结肠癌的预后相关,miR-133和EGFR联合检测有望成为诊疗结肠癌的有效指标和方法。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李美玲
	张光英

关键词 ：结肠肿瘤/病理学, 受体, 表皮生长因子

Abstract：【Objective】 To investigate the expression and clinical significance of miR-133 and epidermal growth factor receptor (EGFR) in colon cancer. 【Methods】 The expressions of miR-133 and EGFR were detected by real-time fluorescent quantitative PCR (RT-PCR); the correlation between miR-133 and EGFR was analyzed by Pearson; the effect of expression level on survival rate was analyzed by Kaplan Meier (K-M) survival curve.【Results】 The expression level of miR-133 in colon cancer tissues was significantly lower than that in normal tissues, while the expression of EGFR was significantly higher than that in normal tissues (P<0.05). There was a negative correlation between the expression of miR-133 and EGFR (r=-0.4941, P<0.01). The expression of miR-133 and EGFR were correlated with clinical stage, lymph node metastasis, TNM stage and pathological grade. The survival rate of patients with high expression of miR-133 was higher than that of the low expression group (P<0.05), while the survival rate of patients with high expression of EGFR was lower than that of the low expression group (P<0.05). 【Conclusion】 The expression of miR-133 and EGFR was increased in colon cancer, and they were negatively correlated with the prognosis of colon cancer. The combined detection of miR-133 and EGFR is expected to be an effective index and method for diagnosis and treatment of colon cancer.

Key words： Colonic Neoplasms/PA Receptor, Epidermal Growth Factor

收稿日期: 2020-07-21

PACS:

R735.35

引用本文:

李美玲, 张光英. miR-133和EGFR在结肠癌组织中的表达及其临床意义[J]. 医学临床研究, 2020, 37(8): 1213-1215.
LI Mei-Ling, ZHANG Guang-Ying. Expression and Clinical Significance of miR-133 and EGFR in Colon Cancer. JOURNAL OF CLINICAL RESEARCH, 2020, 37(8): 1213-1215.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2020.08.029 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2020/V37/I8/1213

[1] Wang W. Molecular subtyping of colorectal cancer: Recent progress, new challenges and emerging opportunities[J].Semin Cancer Biol,2019,55:37-52.
[2] Nguyen LH, Goel A, Chung DC. Pathways of colorectal carcinogenesis[J].Gastroenterology,2020,158(2):291-302.
[3] Lu TX, Rothenberg ME. MicroRNA[J].J Allergy Clin Immunol,2018,141(4):1202-1207.
[4] Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay[J].Nat Rev Genet,2010,11(9):597-610.
[5] Bushati N, Cohen SM. microRNA functions[J].Annu Rev Cell Dev Biol,2007,23:175-205.
[6] da Cunha Santos G, Shepherd FA, Tsao MS. EGFR mutations and lung cancer[J].Annu Rev Pathol,2011,6:49-69.
[7] Tomasello C, Baldessari C, Napolitano M, et al. Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives[J].Crit Rev Oncol Hematol,2018,123:149-161.
[8] Hesari A, Azizian M, Darabi H, et al. Expression of circulating miR-17, miR-25, and miR-133 in breast cancer patients[J].J Cell Biochem,2018.[Online ahead of print]
[9] Zhang G, Wang J, Zheng R, et al. MiR-133 Targets YES1 and inhibits the growth of triple-negative breast cancer cells[J].Technol Cancer Res Treat,2020,19:1533033820927011.
[10] Cheng Z, Liu F, Wang G, et al. miR-133 is a key negative regulator of CDC42-PAK pathway in gastric cancer[J].Cell Signal,2014,26(12):2667-2673.
[11] Liu Y, Han L, Bai Y, Du W, Yang B. Down-regulation of MicroRNA-133 predicts poor overall survival and regulates the growth and invasive abilities in glioma[J].Artif Cells Nanomed Biotechnol,2018,46(1):206-210.
[12] Zhou Y, Wu D, Tao J, et al. MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer[J].Scand J Urol,2013,47(5):423-432.
[13] Schlessinger J. Receptor tyrosine kinases: legacy of the first two decades[J].Cold Spring Harb Perspect Biol,2014,6(3):a008912.
[14] Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer[J].Mol Oncol,2018,12(1):3-20.
[15] Castellanos E, Feld E, Horn L. Driven by mutations: the predictive value of mutation subtype in EGFR-mutated non-small cell lung cancer[J].J Thorac Oncol,2017,12(4):612-623.
[16] Xu MJ, Johnson DE, Grandis JR. EGFR-targeted therapies in the post-genomic era[J].Cancer Metastasis Rev,2017,36(3):463-473.
[17] Koustas E, Karamouzis MV, Mihailidou C, et al. Co-targeting of EGFR and autophagy signaling is an emerging treatment strategy in metastatic colorectal cancer[J].Cancer Lett,2017,396:94-102.
[18] Xu F, Li F, Zhang W, et al. Growth of glioblastoma is inhibited by miR-133-mediated EGFR suppression[J].Tumour Biol,2015,36(12):9553-9558.
[19] Liu S, Chen J, Zhang T, et al. MicroRNA-133 inhibits the growth and metastasis of the human lung cancer cells by targeting epidermal growth factor receptor[J].J BUON,2019,24(3):929-935.
[20] Zhou Y, Wu D, Tao J, et al. MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer[J].Scand J Urol,2013,47(5):423-432.